Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 45

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 45
---
 Chase Bank, N.A., as depositary for the Depositary
Shares, held 67,885,252,427 Ordinary Shares, representing approximately 99.6% of the issued share capital held at that date. As of December
1, 2025, we had two holders of record with an address in the United States. The number of holders of record or registered holders in
the United States or United Kingdom is not representative of the number of beneficial holders or of the residence of beneficial holders.

Based on our share register,
we believe that we are not directly or indirectly controlled by another corporation or government, or by any other natural or legal persons.
There are no arrangements that may result in a change of control. Our major shareholders do not have different voting rights than other
holders of our Ordinary Shares.

To our knowledge, other than
due to the expiration of unexercised warrants held by our shareholders or as otherwise disclosed elsewhere in, or incorporated by reference
into, this prospectus, there has been no significant change in the percentage ownership of our Ordinary Shares held by the principal shareholders
listed above in the last three years.

| 31 |

<div align='center'>DESCRIPTION OF SECURITIES WE ARE OFFERING</div>

We are offering Units, each Unit consisting of one Depositary Share
and two Series L Warrants, each to purchase one Depositary Share. We are also offering to each purchaser whose purchase of Depositary
Shares in this offering would otherwise result in the purchaser, together with its affiliates, beneficially owning more than 4.99% (or,
at the election of the purchaser, up to 9.99%) of our outstanding Ordinary Shares immediately following the consummation of this offering,
the opportunity to purchase, if the purchaser so chooses, Pre-Funded Units containing Pre-Funded Warrants in lieu of the Depositary Shares
that would otherwise result in the purchaser’s beneficial ownership exceeding 4.99% (or, at the election of the purchaser, up to
9.99%) of our outstanding Depositary Shares. For each Pre-Funded Unit we sell (without regard to any limitation on exercise set forth
therein), the number of Units including a Depositary Share we are offering will be decreased on a one-for-one basis. Because two Series
L Warrants are being sold together in this offering with each Depositary Share or, in the alternative, each Pre-Funded Warrant to purchase
one Depositary Share, the number of Series L Warrants